When a Nattokinase Case Report Gets Retracted, the Real Question Is What Medicine Is Afraid to Study

In 2025, a small case series was published in IDCases describing five patients with difficult, persistent post-COVID or post-vaccine syndromes who reportedly improved after a broad treatment protocol that included microbiome restoration, ivermectin, and nattokinase [1]. The paper was not a randomized trial. It was not blinded. It had no control group. It involved only five selected patients from a much larger clinical experience. Those limitations matter, and no honest review should pretend otherwise [1].

But the most interesting part of the paper may not be that it was weak. Weak case reports are published constantly. The more revealing issue is that this one was later retracted, not because the journal identified fabricated data, plagiarism, falsified images, ethical misconduct, or a mathematical error that destroyed the results. Instead, the retraction notice said the paper could encourage premature adoption of an unvalidated treatment, claimed there was no empirical evidence supporting a link between the described pathophysiology and vaccines, and concluded that possible harm outweighed the benefit of keeping it in the literature [2].

That is where this story becomes larger than nattokinase. It becomes a window into how modern medicine treats low-cost, non-patentable interventions when they challenge a protected institutional narrative. A case report is supposed to generate questions, not settle them. If the standard for publishing a case report becomes “do not publish until the treatment has already been validated by comprehensive clinical trials,” then the case-report genre itself loses its purpose [2].

What the Authors Were Actually Claiming

The retracted paper proposed the term “Post-Spike Syndrome,” or PSS, to describe a cluster of symptoms the authors believed could follow either SARS-CoV-2 infection or exposure to mRNA-based therapies. They described fatigue, brain fog, memory impairment, neuropathy, dysautonomia, gastrointestinal symptoms, joint pain, skin manifestations, visual symptoms, sleep disruption, alopecia, and reactivation of pre-existing conditions as part of the syndrome [1].

Their central idea was not simply that patients had vague lingering symptoms. Their claim was more specific. They hypothesized that spike protein exposure may contribute to systemic inflammation, immune activation, endothelial injury, and small-vessel dysfunction. In layman terms, they argued that the problem may not be limited to the lungs or to a past infection. They suspected that spike-related inflammation could disturb blood vessels, nerves, the gut, and immune signaling at the same time [1].

That hypothesis may be controversial, but it is not incoherent. The authors were trying to explain why certain patients developed classical diagnoses that behaved unusually, resisted standard therapy, and then improved after a broad protocol aimed at the gut, inflammation, microcirculation, and spike-related mechanisms [1].

The Protocol Was Broad, Not Just Nattokinase

One of the most important points is that this was not a nattokinase-only paper. The protocol included several components: antibiotics intended to suppress a hypothesized resistant microbiome, probiotics intended to restore Bifidobacterium and related beneficial species, nattokinase at 100 mg twice daily for at least 90 days, and ivermectin at 6 mg per 30 kg three times weekly for at least eight weeks [1].

That makes the results harder to interpret. If a patient improves, the improvement cannot be assigned confidently to nattokinase alone. It could have been the probiotic strategy, the antibiotic phase, ivermectin, nattokinase, the natural course of disease, placebo effect, changes in other medications, or some combination of all of those factors [1].

But that limitation cuts both ways. It means the paper does not prove nattokinase works for PSS. It also means the paper should not be dismissed as if it were making a single simplistic claim. The authors were proposing a systems-based approach to a systems-level problem: gut dysbiosis, inflammatory signaling, vascular irritation, and possible persistent antigenic stimulation [1].

What Happened in the Five Cases

The first case involved a 57-year-old woman with worsening elbow lesions, fatigue, alopecia, memory decline, and tingling. A biopsy confirmed interstitial granulomatous dermatitis. Corticosteroids had not helped. After the protocol, the authors reported complete resolution of PSS symptoms and disappearance of the skin lesions after 60 days [1].

This case mattered to the authors because biopsy findings included inflammatory and vasculitic features. In plain English, the small blood vessels in the affected tissue appeared inflamed. The authors interpreted that as fitting their broader spikeopathy model, where vascular inflammation may be one way spike-related illness expresses itself [1].

The second case involved a 44-year-old woman with fatigue, alopecia, memory decline, brain fog, depression, vertigo, and severe trigeminal neuralgia after COVID infections and one Pfizer dose. She was treated with the protocol along with pain medications and valacyclovir. The authors reported that her PSS symptoms resolved after 60 days and that her trigeminal neuralgia entered remission within 30 days [1].

The third case involved a 52-year-old unvaccinated woman who developed extreme fatigue, shortness of breath, intestinal symptoms, alopecia, shoulder and pelvic girdle pain, and cervical stiffness after COVID infection. She was diagnosed with polymyalgia rheumatica and had elevated inflammatory markers. Prednisolone improved pain but did not resolve fatigue, brain fog, or gut symptoms. After the broader protocol was added, the authors reported symptom resolution and improvement in inflammatory markers, allowing her rheumatologist to reduce prednisolone from 10 mg to 2 mg daily [1].

The fourth case involved a 70-year-old woman with paresthesia, brain fog, dizziness, and fatigue after vaccine exposure and later COVID infection. She improved after two months of treatment, relapsed months later, improved again after restarting therapy, and remained stable with mild residual tingling [1].

The fifth case may have been the most dramatic. A 50-year-old unvaccinated woman developed seizures after encephalitis and later developed PSS-like symptoms after COVID infection. She reportedly had refractory myoclonic seizures despite multiple neurologists, epilepsy specialists, and numerous anticonvulsants. After starting the protocol, the authors reported seizure improvement within one week and full resolution of PSS symptoms after three weeks [1].

This case led the authors to an important inference. They argued that seizure improvement within one week was probably too fast to be explained by microbiome restoration alone. That timing led them to speculate that nattokinase and ivermectin may have had a more immediate effect on spike-related or inflammatory triggers, while the later resolution of broader PSS symptoms fit the expected timeline for microbiome changes [1].

That is not proof. But it is a clinically interesting observation.

The Gut Hypothesis Is the Most Underdeveloped and Most Interesting Part

The paper’s most overlooked contribution may be its focus on the intestinal microbiome. The authors repeatedly emphasized Bifidobacterium depletion, dysbiosis, leaky gut, and possible persistent viral or spike-related activity in the gastrointestinal tract [1].

In layman terms, they were suggesting that the gut may act like a continuing inflammatory engine. If beneficial bacteria are depleted and the gut barrier becomes more permeable, bacterial toxins and inflammatory signals may leak into circulation. That could keep the immune system activated and worsen symptoms far beyond digestion [1].

The paper included a microbiome example showing total depletion of Bifidobacterium in a patient with PSS. The authors interpreted this as support for their view that microbiome disruption may be central to symptom persistence and fluctuation [1].

This part deserves more attention than the retraction controversy gives it. Even if one rejects the authors’ stronger claims about spike protein persistence or mRNA therapies, the gut-immune connection after viral infection is a legitimate area for investigation. The authors’ model may be incomplete, but the clinical pattern they describe is not absurd: persistent symptoms, gut disturbance, inflammatory activation, and neurologic complaints often travel together [1].

Why Nattokinase Was Included

Nattokinase was not included as a random supplement. It was included because the authors viewed PSS as involving microcirculation, endothelial injury, thrombosis-like processes, inflammation, and possible spike-related vascular effects [1].

Nattokinase is a serine protease produced during the fermentation of soybeans into natto. It is best known for fibrinolytic activity, meaning it helps break down fibrin, the protein mesh involved in clot structure. In cardiovascular research, nattokinase has been studied for effects on clotting, blood flow, lipids, and atherosclerotic markers [3].

A 2022 biochemical study in Molecules shows that nattokinase degraded the SARS-CoV-2 spike protein in a dose- and time-dependent manner in laboratory models [4]. That finding does not prove nattokinase clears spike protein in humans. A cell or biochemical study is not a clinical trial. But it does provide a plausible mechanistic reason why clinicians interested in spike-related illness might consider studying nattokinase further [4].

That is the key distinction. The biochemical evidence is not a treatment protocol. It is a reason to investigate.

What the Retraction Got Right

The retraction notice was correct about one thing: this case series does not establish safety, efficacy, or causality [2].

Five cases cannot necessarily prove that the protocol works. Retrospective chart review cannot exclude placebo effect, regression to the mean, spontaneous recovery, selection bias, or clinician expectation. A four-part protocol cannot identify which component mattered. A private-clinic case series cannot substitute for randomized controlled trials [1].

However, although those are serious limitations, the authors themselves described the report as observational, descriptive, and hypothesis-generating [1].

A responsible article should not tell patients to copy this protocol. It should not claim nattokinase cures PSS. It should not imply that ivermectin, antibiotics, probiotics, or nattokinase are proven treatments for post-COVID or post-vaccine syndromes. They are not proven by this paper [1][2].

What the Retraction Got Wrong

Yet, the problem is that the retraction notice did not merely say, “This paper is weak.” It went further. It treated the possibility of premature adoption as a reason to remove a case report from the literature [2].

That is a dangerous standard if applied consistently. Case reports are inherently preliminary. They exist because medicine has always advanced partly through careful observation of unusual clinical patterns. A case report does not become invalid because it describes an unvalidated intervention. That is often the entire point [2].

The notice also claimed there was no empirical evidence supporting a link between the described pathophysiology and vaccines [2]. That categorical language is too broad for a scientific retraction notice. Even if one disputes the authors’ full PSS model, it is no longer serious to pretend that mRNA vaccines have no empirically documented adverse-event pathways at all. This part of the retraction notice is contradicted by other regulatory and peer-reviewed materials, including myocarditis and pericarditis acknowledgments and adverse-event analyses [5].

The more careful position would have been: “The evidence presented in this case report is insufficient to establish that these five patients’ illnesses were caused by vaccination or spike protein persistence.” That would be fair. But saying there is “no empirical evidence” for the described pathophysiology is much broader, and it reads less like scientific caution than institutional overcorrection [2][5].

The Real Issue: What Kind of Evidence Is Allowed to Exist?

The deeper question is not whether this case series proves anything. It does not.

The deeper question is whether weak but transparent clinical observations should remain available for scrutiny, especially when they concern a low-cost, non-patentable intervention that is unlikely to attract pharmaceutical-scale funding.

That is where skepticism toward the mainstream medical system is justified. Modern evidence hierarchies often sound neutral, but they are not neutral in practice. A patented drug can attract the investment needed for large trials. A food-derived enzyme like nattokinase usually cannot. When journals demand pharmaceutical-grade evidence before allowing even preliminary clinical observations to remain visible, they create a standard that low-profit interventions are structurally unable to satisfy.

This does not prove a conspiracy. It reveals an incentive problem.

The institutions that claim to protect patients from “unproven” interventions often provide no realistic pathway for proving those interventions when no company can own the molecule. The result is a circular trap: the observation is dismissed because it lacks trials, and the trials never happen because the intervention cannot generate enough exclusive profit to fund them.

What Should Have Happened Instead

The better response would not have been uncritical acceptance. It would have been a formal editorial note.

The journal could have left the paper in place with a clear warning: this is a retrospective five-patient case series, the protocol contains multiple simultaneous interventions, causality is not established, vaccine attribution is speculative, and the treatment should not be adopted without controlled clinical evidence.

That would have protected readers without erasing the observation.

Science is supposed to be a record of what was observed, what was hypothesized, and what remains uncertain. Retraction should be reserved for deeper failures of integrity or reliability, not for discomfort with where an observation might lead.

Why This Still Matters for Nattokinase

The lesson is to recognize that nattokinase still sits at the intersection of several biologically relevant systems: fibrin breakdown, microcirculation, vascular inflammation, and possibly spike-protein degradation in laboratory models [3][4].

That makes it worthy of study.

The case report is not the proof. It is a signal. The biochemical work is not the proof. It is a mechanism. The cardiovascular literature is not the proof of PSS benefit. It is background plausibility.

But when all of these pieces are viewed together, they justify further investigation rather than removal from the scientific record.

Conclusion

The retracted IDCases paper was weak evidence, but weak evidence is not the same as worthless evidence. It described five complex patients, a coherent clinical hypothesis, a broad intervention, and reported improvements that deserve follow-up in better-designed studies [1].

The retraction notice may have been written in the language of public safety, but it also reflects a broader problem in modern medicine: low-cost, non-patentable interventions are often held to evidentiary standards that the current funding system will never help them meet [2].

The honest conclusion is that the question remains open, the mechanism is plausible enough to study, the safety profile deserves fair comparison against available options, and the clinical observations should have been challenged, contextualized, and investigated rather than buried.

That is how science is supposed to work.

References

[1] Zeballos, R. S., da Silva Helbingen, M. F., Porto de Melo, P. M., Cardoso Alves, F. E., Salvino, C. R., Seródio, E. P., & de Carvalho, E. R. M. (2025). Post spike syndrome (PSS): Simple solution leading to resolving results, five cases report. IDCases, 41, e02278. https://doi.org/10.1016/j.idcr.2025.e02278. Retracted.

[2] Zeballos, R. S., da Silva Helbingen, M. F., Porto de Melo, P. M., Cardoso Alves, F. E., Salvino, C. R., Seródio, E. P., & de Carvalho, E. R. M. (2026). Retraction notice to “Post spike syndrome (PSS): Simple solution leading to resolving results, five cases report” [IDCases 41 (2025) e02278]. IDCases, 43, 102449.

[3] Chen, H., Chen, J., Zhang, F., Li, Y., Wang, R., Zheng, Q., Zhang, X., Zeng, J., Xu, F., & Lin, Y. (2022). Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in cardiovascular medicine, 9, 964977. https://doi.org/10.3389/fcvm.2022.964977

[4] Tanikawa, T., Kiba, Y., Yu, J., et al. (2022). Degradative effect of nattokinase on spike protein of SARS-CoV-2. Molecules, 27(17), 5405. https://doi.org/10.3390/molecules27175405

[5] Dar-Odeh, N., Abu-Hammad, O., Qasem, F., Jambi, S., Alhodhodi, A., Othman, A., Abu-Hammad, A., Al-Shorman, H., Ryalat, S., & Abu-Hammad, S. (2022). Long-term adverse events of three COVID-19 vaccines as reported by vaccinated physicians and dentists, a study from Jordan and Saudi Arabia. Human vaccines & immunotherapeutics, 18(1), 2039017. https://doi.org/10.1080/21645515.2022.2039017

[6] Lampe, B. J., & English, J. C. (2016). Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. Food and Chemical Toxicology, 88, 87–99. https://doi.org/10.1016/j.fct.2015.12.010

*The matters discussed in this article are for informational purposes only and not medical advice. Please consult your healthcare practitioner on the matters discussed herein.

*These statements have not been evaluated by the Food and Drug Administration. Healthmasters' products are not intended to diagnose, treat, cure, or prevent any disease.